DATA GRAPHICS | Data Byte
BioNTech strikes another deal with Chinese biotech, third YTD
After string of deals granting access to its COVID-19 vaccine in Asia, the German biotech has begun in-licensing cancer tech from the region
July 25, 2023 12:20 AM UTC
As Western biotechs increasingly turn to China for cancer innovation, BioNTech is now among their number. Prior to this year, nearly all of the German company’s Asia deals went the other direction, providing access to its COVID-19 vaccine. But this month saw BioNTech make its second and third deals sourcing cancer technology from Chinese biotechs.
On July 20, BioNTech SE (NASDAQ:BNTX) announced a deal in which Zhuhai-based Biotheus Inc. granted it exclusive options to a clinical mAb and preclinical bispecific antibody. BioNTech also received an exclusive license to existing panels of VHH binders against multiple targets, along with options to request generation of new panels against targets of interest...